Are MAP kinases drug targets? Yes, but difficult ones.
Pharmaceutical companies are facing an increasing interest in new target identification and validation. In particular, extensive efforts are being made in the field of protein kinase inhibitors research and development, and the past ten years of effort in this field have altered our perception of the potential of kinases as drug targets. Therefore, in the drug discovery process, the selection of relevant, susceptible protein kinase targets combined with searches for leads and candidates have become a crucial approach. The success of recent launches of protein kinase inhibitors (Gleevec, Imatinib, Sutent, Iressa, Nexavar, Sprycel) gave another push to this field. Numerous other kinase inhibitors are currently undergoing clinical trials or clinical development. Some questions are nevertheless unanswered, mostly related to the great number of known kinases in the human genome, to their similarity with each other, to the existence of functionally redundant kinases for specific pathways, and also because the connection between particular pathways and diseases is not always clear. The review is leading the reader through a panoramic view of protein kinase inhibition with a major focus on MAPK, successful examples and clinical candidates.
Margutti
Simona
S
Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry; Eberhard Karls University of Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.
Laufer
Stefan A
SA
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D015894:Genome, Human; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects*; D015394:Molecular Structure; D015398:Signal Transduction / Q000187:drug effects; D013379:Substrate Specificity
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D020928:Mitogen-Activated Protein Kinases